Home › NDC Lookup › RxCUI directory › RxCUI 2571079

Maralixibat 9.5 MG/ML Oral Solution — RxCUI 2571079

RxNorm drug concept · Semantic clinical drug
RxCUI 2571079 Semantic clinical drug · SCD ● Current RxNorm concept 6 FDA products 6 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2571079
Official nameMaralixibat 9.5 MG/ML Oral Solution
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asmaralixibat (as maralixibat chloride 10 MG/ML) 9.5 MG/ML Oral Solution
FDA products mapped6
Package NDCs mapped6
Reported Medicaid activity (SDUD)1,179 prescriptions · 13 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Maralixibat: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Livmarli isn't a cure for Alagille syndrome or PFIC — it's designed to treat one of the most difficult symptoms of these conditions: intense, persistent itching caused by bile acid...
  • What exactly does Livmarli do, and will it cure my child's liver condition?
  • Yes, timing around meals really does matter. Livmarli should always be taken 30 minutes before a meal — whether you're using the oral solution or the tablet. For Alagille syndrome,...
  • How should we give Livmarli, and does it matter when we give it with food?
📖 Read our full Maralixibat guide →

🕸️ Concept Web — How Maralixibat 9.5 MG/ML Oral Solution Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Maralixibat 9.5 MG/ML Oral Solution RxCUI 2571079

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Maralixibat 2571074
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Livmarli 2571080
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Maralixibat Oral Solution 2571078
    • Maralixibat Oral Liquid Product 2571077
    • Maralixibat Oral Product 2571076
    • Maralixibat Oral Solution [Livmarli] 2571084
    • Livmarli Oral Liquid Product 2571083
    • Livmarli Oral Product 2571082
    • Oral Solution 316968
    • Oral Liquid Product 1151137
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Maralixibat 9.5 MG/ML SCDC · 2571075
  • Maralixibat Oral Solution SCDF · 2571078
  • Maralixibat Oral Liquid Product SCDG · 2571077
  • Maralixibat Oral Product SCDG · 2571076

Brand-Name Concepts

  • Maralixibat 9.5 MG/ML Oral Solution [Livmarli] SBD · 2571085
  • Maralixibat 9.5 MG/ML [Livmarli] SBDC · 2571081
  • Maralixibat Oral Solution [Livmarli] SBDF · 2571084
  • Livmarli Oral Liquid Product SBDG · 2571083
  • Livmarli Oral Product SBDG · 2571082
  • Livmarli BN · 2571080

📦 FDA Products & Package NDCs

6 products · 6 package NDCs
6 package NDCs map to RxCUI 2571079 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
79378-0110-01 1 BOTTLE in 1 CARTON (79378-110-01) / 30 mL in 1 BOTTLE Livmarli Mirum Pharmaceuticals Inc. 2021-09-29
79378-0111-01 1 BOTTLE in 1 CARTON (79378-111-01) / 30 mL in 1 BOTTLE Livmarli Mirum Pharmaceuticals Inc. 2024-07-24
79378-0210-30 1 BOTTLE in 1 CARTON (79378-210-30) / 30 TABLET in 1 BOTTLE Livmarli Mirum Pharmaceuticals Inc. 2025-04-10
79378-0215-30 1 BOTTLE in 1 CARTON (79378-215-30) / 30 TABLET in 1 BOTTLE Livmarli Mirum Pharmaceuticals Inc. 2025-04-10
79378-0220-30 1 BOTTLE in 1 CARTON (79378-220-30) / 30 TABLET in 1 BOTTLE Livmarli Mirum Pharmaceuticals Inc. 2025-04-10
79378-0230-30 1 BOTTLE in 1 CARTON (79378-230-30) / 30 TABLET in 1 BOTTLE Livmarli Mirum Pharmaceuticals Inc. 2025-04-10
Observed labelers: Mirum Pharmaceuticals Inc. (6) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.